The pharmaceutical industry is currently engaged in an intense competition to maximize weight reduction percentages. The evolution from standard glucagon-like peptide-1 (GLP-1) receptor agonists to dual and triple agonists and even more complex combinations has fundamentally shifted clinical benchmarks and investor expectations. We are now witnessing targets of 30% to 40% of body mass, a range that could be achieved only through bariatric surgery previously. However, this numerical obsession is starting to decouple the metric of weight loss from the real objective of metabolic health. By focusing purely on total mass reduction, the industry risks sacrificing metabolic integrity and vital physiological components like muscle mass in the pursuit of higher percentages (Figure 1).
Han et al. (Fri,) studied this question.